jfm1330 wrote: SPCEO1 wrote:
And why would you highlight the convertible in your comments if you are trying to attract new investors?
In a nutshell this is depicting what is totally wrong with this board right now. Just before that comment, SPCEO alluded to possible sales numbers manipulation by the management, and then he would want them to hide important material facts in their presentation to attract new investors. This is close to inciting fraud, maybe not in a legal sense, but at least in the moral sense. This would clearly be a lie by omission. The obssession with self-promotion by the company and the short term stock price here is going into crazy territory. Sorry to say that, but from the outside it's the way it looks right now.
When you read the comments here, and it intensified into crazy territory lately, it is as if the management of this company, with the actual CEO, and the previous one, are all a bunch of incompetents Canadians. That the company would be in much better hands if ran by Americans. All that while crying that that their great clinical programs are not well valued by the market. So on the one hand they are great on the most important thing, having good programs out of great science, but they should promote them like used cars salsemen before they have real solid data to do so. Sorry, this is not the way it works. These guys in the management won't invent data and they won't hide material facts just for the sake of having a higher stock price in the very short term. Many here are asking them to do just that and they won't. They will talk with you to try to bring you back to some reason, but they won't lie to promote the stock price in the very short term. They know this will come with good results in clinical trials ans good news on the regulatory side.
I understand long time shareholders, it has been a frustrating journey and most missed the opportunity to cash in big in 2018. That being said, past frustrations won't change anything in the present and the future. Also, crazy valuations of other companies is not a reason to think that those should apply automaticly to Thera. On the other hand, I am sure that if great reasults happen in cancer, the market will reflect it swiftly.
Here is what I think about this company:
- Stock price will go up with actual good results, not on promises
- Management is very competent, dedicated and honest
- The actual BOD is essentially the one that allowed the company to acquire Trogarzo, to be a player in NASH and gave the green light to acquire the oncology platform (Katana)
- The last financing was made at the right time with the best offer they were able to find
- Going for a huge market like NASH involved a need for a lot of cash. The level of dilution is directly linked to that
- With this financing in the bank, the short term stock price is irrelevant, it will all depend on results
-The most important thing is the quality of the science and proper execution to show it
- The positive message of the CEO about oncology and NASH programs is very clear, but he cannot go ahead of results
-By far, the main job of management is to execute on the real job they have to do to get good and real results, not act as full time promoters for the short term stock price
-Paul Levesque cannot manage the company while taking on his back the whole history of underachievments of Thera and the frustrations accumulated by long time shareholders
A potential investor knowing little about Thera that would come here lately to learn more about this company would think this company is led by a bunch of incompetents on the margin of criminality. A management that tries to steal long time shareholders to benefit other people in cahoots with them. This is totally crazy and false. Sorry to state it so bluntly. Many here would need to reconnect with reality. There is some kind of schizophrenia going on here. On one side almost all recognize how great the science ans clinical programs appear to be, but on the other hand are denigrating the people that brought that to the company. It does not add up.
Again. I know I am alone in my camp, but I am sure I am right on that. At least somebody will have said it.
This board has been a great place to discuss for a long while, we were right on many things, but in the last few years we have been wrong on the most important thing, commercial potential of Trogarzo. Most of the intense frustration about the stock price here stems from that mistake. The money was there in May-July 2018 to be cashed in, and most here, including myself did not.
I think the Trogarzo story was a lesson for Thera, the management did not make promises on sales, but they hinted at much better numbers than what has been achieved. I think this is now part of the corporate memory there. Easy to understand why they are careful not to make promises or just hint to future results that may not materialize. To be promotional, you need to push forward hypothetical positive outcomes, even when there is no certainty about that. I think Thera is not willing to play that game and rightly so. I think Levesque is focusing on good execution after he thouroughly analyzed each dossier, that's the way a good CEO should work. If the analysis and execution are good, odds of success will follow.
I have old virtual friends here. I know my message is very harsh, but, if possible, don't take it as a personal insult, but more a wake up call attempt. It relates only to what is written here. I just profoundly disagree with most of it and strong words are necessary when you are in overwhelming minority. I know my message won't change the position of most, but, at least, it is there for the record. You can blast me in return, fair game, but I won't argue any further. I will still come here because sometimes good nuggets of infos are discovered, but I skip most messages as soon as I see it is worthless, at least in my view. So I will stay away for a good while, maybe forever, but at least until this board is in a better mood and hopefully it will come with good results in oncology.